Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Glycine, Placebo.
- Who it may be relevant to
- Registry conditions: Metabolic Dysfunction Associated Fatty Liver Disease. Basic parameters: 21 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Investigating the Effects of Dietary Glycine Supplementation in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Overview
The purpose of this research study is to determine whether taking glycine, a naturally occurring amino acid, as a supplement improves liver health measurements in individuals with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD). This project will be divided into two parts. The first part will be a case-control study comparing parameters of glycine-dependent metabolic pathways between individuals with MASLD and healthy controls. The second part will be a randomized placebo-controlled trial (RCT) to evaluate the impact of 26-week dietary glycine supplementation on parameters of liver health versus 26-week placebo in patients with MASLD.
Detailed description
This study will recruit 60 participants with MASLD and 30 healthy controls.
Following written informed consent, subjects will be screened. Eligible study subjects will return to undergo MRI scans of the abdomen to measure fat, iron, fibro-inflammation in the liver. Baseline metabolic measurements will include clinical laboratory tests, anthropometrics, body composition, resting energy expenditure, and comprehensive metabolomic profiling. Medical history, physical activity, dietary intake, and sleep quality will also be documented.
Study subjects in with MASLD will be randomized to consume either 9g/day of glycine capsules or placebo capsules for the next 26 ± 4 weeks. Subjects MASLD will be reviewed at 12 ± 4 weeks following the initiation of glycine or placebo to monitor compliance and adverse events.
The final study visit (for subjects with MASLD) will be scheduled at 26 ± 4 weeks after initiation of glycine or placebo. The study subjects will undergo metabolic measurements similar to those performed during the baseline visit.
Interventions
- Dietary supplement Glycine
9g/day of glycine in capsules - Dietary supplement Placebo
Microcrystalline cellulose in identifically-looking capsules
Primary outcome measures
- Changes in hepatic Magnetic Resonance Imaging-Proton Density Fat Fraction and concentrations of acylglycines, glutathione, cytokines, oxidative stress markers, and 1-carbon cycle metabolites from baseline to 26 weeks [Time frame: From the initiation to end of the treatment at 26 weeks]
- Differences in concentrations of acylglycines, glutathione, cytokines, oxidative stress markers, and 1-carbon cycle metabolites between subjects with MASLD and controls [Time frame: From enrollment to the completion of baseline metabolic assessment (within 8 weeks)]
Eligibility criteria
Inclusion criteria
All subjects:
- Age 21-70 years
- Ability to provide informed consent.
MASLD group:
- Hepatic steatosis on MRI
- BMI of 25-50 kg/m2
Controls:
- Absence of hepatic steatosis on MRI
- BMI of 18.5-24.9 kg/m2
- No chronic disease
- No long-term medications
Exclusion criteria
- Uncontrolled diabetes (HbA1c > 8%)
- Type 1 Diabetes Mellitus
- Clinically significant anemia (Haemoglobin < 10 g/dL)
- Chronic liver disorders (except MASLD) such as Hepatitis B, Hepatitis C, Wilson's disease, hemochromatosis, autoimmune hepatitis, chronic cholestatic disorders, and liver cirrhosis
- Drugs that may induce hepatic steatosis, such as methotrexate, amiodarone, tamoxifen, or Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)
- Glomerular filtration rate (GFR < 30 ml/min)
- Serum alanine transaminase (ALT) > 3x upper limit of normal (ULN)
- Serum aspartate transaminase (AST) > 3x ULN
- Liver cirrhosis
- Significant alcohol consumption (> 20g/day for women and >30g/day for men)
- Receiving weight loss medications or GLP-1 receptor agonists
- Pregnancy
- Uncontrolled thyroid disease
- Previous bariatric surgery
- Weight loss > 5% in the past 1 month
- Metallic implants (including incompatible pacemakers, AICD, metallic heart valves) or other contraindications to MRI
- Claustrophobia
- Any factors likely to limit adherence to study protocol (e.g., dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other, or family members)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07285135 · 2025-1240 · CSAINV25jan-0007